D.E. Shaw & Co
PHAS

D.E. Shaw & Co’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

D.E. Shaw & Co’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,796
Closed -$31K – 6170
2021
Q4 		$31K Sell
11,796
-66,751
-85% -$202K ﹤0.01% 5267
2021
Q3 		$244K Buy
78,547
+60,873
+344% +$203K ﹤0.01% 4477
2021
Q2 		$66K Buy
+17,674
New +$58.8K ﹤0.01% 4605

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
TCM
Towercrest Capital Management Newtown, Pennsylvania $642M AUM 11.71% 1-Year Est. Return
VPW
Vericrest Private Wealth Newtown, Pennsylvania $111M AUM

D.E. Shaw & Co's PHAS Position: Q1 2022 in Review

D.E. Shaw & Co sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q1 2022, closing a stake of 11,796 shares — an estimated $31K sold.

D.E. Shaw & Co first reported a position in PHAS in Q2 2021 and held it in 3 quarters. The position peaked at $244K in Q3 2021. 56 funds tracked by Wall St. Rank hold PHAS as of Q1 2022.

  • D.E. Shaw & Co reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 11,796 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $31K.
  • D.E. Shaw & Co first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $244K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.